These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 17026795)

  • 1. Phase III multicenter randomized clinical trial to evaluate the safety and efficacy of CoFactor/5-fluorouracil/bevacizumab versus leucovorin/5-fluorouracil/bevacizumab as initial treatment for metastatic colorectal carcinoma.
    Saif MW; Merritt J; Robbins J; Stewart J; Schupp J
    Clin Colorectal Cancer; 2006 Sep; 6(3):229-34. PubMed ID: 17026795
    [No Abstract]   [Full Text] [Related]  

  • 2. Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.
    Whyte S; Pandor A; Stevenson M; Rees A
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):47-53. PubMed ID: 21047491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.
    Hochster HS
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S8-14. PubMed ID: 17145525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Improving longevity in advanced intestinal cancer].
    Schmoll HJ
    Krankenpfl J; 2005; 43(1-3):48. PubMed ID: 15912837
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301.
    Chen HX; Mooney M; Boron M; Vena D; Mosby K; Grochow L; Jaffe C; Rubinstein L; Zwiebel J; Kaplan RS
    J Clin Oncol; 2006 Jul; 24(21):3354-60. PubMed ID: 16849749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial.
    Tyagi P; Grothey A
    Clin Colorectal Cancer; 2006 Nov; 6(4):261-4. PubMed ID: 17241510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
    Dohn LH; Jensen BV; Larsen FO
    Acta Oncol; 2010 Apr; 49(3):395-6. PubMed ID: 20001495
    [No Abstract]   [Full Text] [Related]  

  • 8. Current role of bevacizumab in colorectal cancer.
    Saltz L
    Clin Adv Hematol Oncol; 2009 Jun; 7(6):375-6. PubMed ID: 19606071
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety of 10 min infusion of bevacizumab in combination with 5FU-based chemotherapy in non-selected metastatic colorectal cancer patients.
    Coriat R; Mir O; Chaussade S; Goldwasser F
    Dig Liver Dis; 2011 Mar; 43(3):248-9. PubMed ID: 21145299
    [No Abstract]   [Full Text] [Related]  

  • 10. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
    Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H
    Dis Colon Rectum; 2011 Aug; 54(8):1026-35. PubMed ID: 21730794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.
    Arkenau HT; Arnold D; Cassidy J; Diaz-Rubio E; Douillard JY; Hochster H; Martoni A; Grothey A; Hinke A; Schmiegel W; Schmoll HJ; Porschen R
    J Clin Oncol; 2008 Dec; 26(36):5910-7. PubMed ID: 19018087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.
    Hurwitz H; Saini S
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S26-34. PubMed ID: 17145522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapy of colorectal carcinoma. To combine saves lives].
    Arnheim KE
    MMW Fortschr Med; 2004 Jan; 146(1-2):14. PubMed ID: 18441573
    [No Abstract]   [Full Text] [Related]  

  • 14. [Antibody treatment in colorectal cancer--what the surgeon needs to know].
    Thalheimer A; Illert B; Reimer P; Bueter M; Thiede A; Gasser M; Fein M; Waaga-Gasser AM; Meyer D
    Zentralbl Chir; 2008 Apr; 133(2):101-6. PubMed ID: 18415895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab in combination with 5-fluorouracil-based chemotherapy in the second-line treatment of metastatic colorectal cancer.
    Benson AB
    Clin Adv Hematol Oncol; 2006 Oct; 4(10):747. PubMed ID: 17111559
    [No Abstract]   [Full Text] [Related]  

  • 16. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
    Hurwitz HI; Fehrenbacher L; Hainsworth JD; Heim W; Berlin J; Holmgren E; Hambleton J; Novotny WF; Kabbinavar F
    J Clin Oncol; 2005 May; 23(15):3502-8. PubMed ID: 15908660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chemotherapy with bevacizumab (BV)+modified FOLFOX6 for unresectable colorectal cancer].
    Matsumoto R; Kuroda T; Yamada H; Hasegawa K; Mamiya Y; Kon A
    Gan To Kagaku Ryoho; 2009 Nov; 36(12):2207-9. PubMed ID: 20037372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-fluorouracil, leucovorin and oxaliplatin plus bevacizumab in the first-line treatment of metastatic colorectal cancer: a single-institute study.
    Bir A; Tan W; Wilding GE; Lombardo J; Fakih MG
    Oncology; 2007; 72(1-2):4-9. PubMed ID: 17971679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.
    Sobrero A; Ackland S; Clarke S; Perez-Carrión R; Chiara S; Gapski J; Mainwaring P; Langer B; Young S;
    Oncology; 2009; 77(2):113-9. PubMed ID: 19628950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer.
    Cohen MH; Gootenberg J; Keegan P; Pazdur R
    Oncologist; 2007 Mar; 12(3):356-61. PubMed ID: 17405901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.